US-based pharmaceutical and biotechnology giant Pfizer is set to acquire the remaining shares of Trillium Therapeutics in a deal worth $2.26 billion, media reports said. The drugmaker will buy the shares for $18.50 a piece, representing a 203.8 percent premium.
Pfizer previously bought stakes in Trillium Therapeutics last year in a deal worth $25 million. Trillium develops drugs that boost patients’ innate immune systems to detect and destroy cancer cells.
Recently, the Food and Drug Administration (FDA) granted full approval to Pfizer-BioNTech’s coronavirus vaccine for people who are 16 and older.
Dr. Janet Woodcock, the acting FDA commissioner, said in a statement, “While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated. Today’s milestone puts us one step closer to altering the course of this pandemic in the US.”
In May, it was reported that Spain is set to receive almost 94 million doses of Pfizer vaccine to help fight the country against Covid-19. A government spokeswoman announced that between December 2021 and June 2023, the country will receive these doses, which is a part of the European Union purchase.
She also said that the number of vaccine doses sent to the country is equivalent to twice the target population. It is also important to keep in mind that 8.1 million people have already received their full course of vaccinations in Spain.